CEO INTERVIEW: AnnovisBio, Inc. ($ANVS) gets FDA green light to initiate Phase 3 Alzheimer's study
The Harvest Podcast di Carmel Fisher
Note sull'episodio
Watch and Subscribe on Youtube: https://www.youtube.com/@TheHarvestPodcastwithCarmel
In this episode, Dr. Maccecchini discusses the company’s recent meetings with the U.S. Food and Drug Administration (FDA), which resulted in clearance to initiate pivotal Phase 3 studies of buntanetap in early-stage AD patients.
“To date, we have conducted four small studies in Alzheimer’s, an ...
Parole chiave
Capitalmarketsnysebiosciencesceointerviewscarmel fisherthe harvest podcastbiopharmabusiness capital marketsannovis bioalzheimersparkinsonsbiotherapeuticsbioscienceANVS$ANVSphase3fda clearancebuntanetapdiseaseneurogenerativeceo interviews